2 Big Pharma Giants Headed in Opposite Directions

Earnings season's tearing through the health care sector, and Bristol-Myers Squibb (NYSE: BMY  ) and GlaxoSmithKline (NYSE: GSK  )  have faced off with investors this week. Bristol hit all the right points: The company saw its sales climb by 9% for the quarter, and drugs such as skin cancer treatment Yervoy are helping this big pharma staple overcome the residual effects of the patent cliff.

It's a different story for GlaxoSmithKline. The company's corruption probe in China has come back to haunt its finances. Glaxo's China sales dropped by more than 60% for the quarter, and the company's leadership isn't yet sure when the negative impact from China will end.

Where Bristol's stock has soared recently, Glaxo's shares haven't been able to generate much momentum. But where are these two big pharma giants headed in the near future? In the video below, Fool contributor Dan Carroll takes you through Bristol-Myers Squibb's and GlaxoSmithKline's third quarter takeaways and whether either of these stocks is worth your investment heading forward.

More dividend ideas
Big pharma stocks like Glaxo and Bristol have long been strong picks for any dividend investor, but are times changing on the markets? If you're an investor who prefers returns to rhetoric, you'll want to read The Motley Fool's new free report "5 Dividend Myths... Busted!" In it, you'll learn which stocks provide premium growth and whether bigger dividends are better. Click here to keep reading.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2699441, ~/Articles/ArticleHandler.aspx, 8/1/2014 9:37:01 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement